Modalities - Momentum Biotechnologies

We offer support for the development of a broad range of therapeutic modalities.

Thanks to our extensive service portfolio, we can support you from the early stages of target discovery and validation through high-throughput screening and into preclinical research and characterization. We have experience collaborating with clients to develop novel next-generation therapeutics, as well as established modalities. Beyond our screening services, which focus on small-molecule drug discovery, our proteomic and chemoproteomic technologies can advance the development of virtually any therapeutic class.

Radiotherapeutics
Harness the ultra-sensitive analytic power of ICP-MS for radioligand discovery and development
Molecular Glues
Induce or stabilize protein-protein interactions for therapeutic applications
Targeted Degraders
Induce target degradation with precision and potency
Covalent Drugs
Unlock potent and selective therapeutics through covalent binding
DNA- and RNA-Targeting Drugs
Accelerate the development of DNA- and RNA-targeted small-molecule therapeutics
Oligonucleotide Therapeutics
Modulate protein expression and splicing with RNA-binding ASOs and RNAi
Kinase Inhibitors
Develop selective and potent protein kinase inhibitors
ADCs
Targeted immunotherapeutics for cancer treatment and beyond
Gene Therapies
Modify genetic content and expression to enable new frontiers of disease treatment
Cell Therapies
Harness the power of cell therapy to overcome unmet disease challenges